Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTeam17 Regulatory News (TM17)

  • There is currently no data for TM17

Grant of Options

18 Dec 2018 07:00

RNS Number : 7500K
Team17 Group PLC
18 December 2018
 

18 December 2018

Team17 Group plc

("Team17", the "Group" or the "Company")

 

Grant of Options

 

Team17 Group plc (AIM:TM17) announces that it has granted options (the "Options") over 141,892 new ordinary shares of 1 pence each in the Company ("Ordinary Shares") under the rules of its Long Term Incentive Plan (the "Plan") to a director as follows:

 

Director

Position

Number of options granted

Total options held following this grant

Jo Jones

Chief Financial Officer

141,892

141,892

 

The Options are granted at an Award Price of nil over 141,892 shares.

 

The Options are granted subject to the rules of the Plan and performance targets based on EPS and Total Shareholder Return.

 

Details of the director's resulting holdings of Ordinary Shares and options over Ordinary Shares are as follows:

 

Name

Total No. of Options

No. of Existing Ordinary Shares

Jo Jones

141,892

nil

 

 

For further information please contact:  

 

Team17 Group plc 

Debbie Bestwick MBE, Chief Executive Officer 

Jo Jones, Chief Financial Officer

 

via Vigo Communications 

+44 (0)20 7390 0238 

GCA Altium (Nominated Adviser)

Phil Adams / Adrian Reed / Paul Lines 

 

+44 (0)845 505 4343 

Berenberg (Broker)

Chris Bowman / Toby Flaux / Marie-Agnes Stolberg 

 

+44 (0)20 3207 7800 

Vigo Communications (Financial Public Relations) 

Jeremy Garcia / Fiona Henson / Charlie Neish

team17@vigocomms.com

+44 (0)20 7390 0238 

 

Notes to Editors

Founded in 1990, Team17 Group plc is a leading international video games label and creative partner for independent developers. The portfolio comprises over 100 games, including The Escapists, Genesis Alpha One, Overcooked, Yoku's Island Express, Yooka-Laylee, the Worms franchise and many more from developers around the world. Visit www.team17.com for more info.

 

 

EU Market Abuse Regulation

The notifications set out below are provided in accordance with the requirements of the EU Market Abuse Regulation.

 

1

Details of the person discharging managerial responsibilities

a)

Name

Jo Jones

2

Reason for the notification

a)

Position/status

Chief Financial Officer

b)

Initial notification/amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Team17 Group plc

b)

LEI

2138006EUUCCL4ZI5E51

4

Details of the transaction(s): sections to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of financial instrument, type of instrument

 

Identification code

Options over ordinary shares of 1 pence each

 

 

ISIN: GB00BYVX2X20

b)

Nature of the transaction

Grant of options over 141,892 ordinary shares of 1 pence each

c)

Prices(s) and volume(s)

Price(s):

Volume(s)

NIL

141,892

d)

Aggregated information

Not applicable

e)

Date of transaction

17 December 2018

f)

Place of the transaction

London Stock Exchange

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHFKODBFBDDABD
Date   Source Headline
23rd Jan 20257:00 amRNSTrading Update and Change of Company Name
15th Nov 202412:30 pmRNSIssue of Shares and Total Voting Rights
15th Nov 202410:00 amRNSEstablishment of New Option Plan, Grant of Options
7th Nov 20243:33 pmRNSDirector Dealing
6th Nov 20247:00 amRNSChange of Nomad & Directors Disclosures
1st Nov 20247:00 amRNSHoldings in Company
30th Oct 20247:00 amRNSBoard Change
24th Oct 20244:20 pmRNSHoldings in Company
14th Oct 20247:00 amRNSDirector/PDMR Shareholding
1st Oct 20247:00 amRNSChange of Nominated Advisor
17th Sep 20247:00 amRNSHalf Year Results
11th Sep 20243:02 pmRNSDirector/PDMR Shareholding
11th Sep 20247:00 amRNSHoldings in Company
4th Sep 20242:25 pmRNSHoldings in Company
28th Aug 20247:00 amRNSNotice of Results & Analyst/Investor Presentations
22nd Aug 20247:00 amRNSHoldings in Company
14th Aug 20244:15 pmRNSDirector/PDMR Shareholding
17th Jul 20247:00 amRNSTrading Update
11th Jul 20245:03 pmRNSDirector/PDMR Shareholding
9th Jul 20244:18 pmRNSDirector/PDMR Shareholding
19th Jun 202411:15 amRNSResult of AGM
13th Jun 20249:20 amRNSDirector/PDMR Shareholding
3rd Jun 20247:00 amRNSAppointment of Joint Corporate Broker
23rd May 202412:00 pmRNSPosting of Annual Report and Notice of AGM
13th May 20244:55 pmRNSDirector/PDMR Shareholding
16th Apr 20247:00 amRNSUnaudited Final Results 2023
12th Apr 20241:16 pmRNSDirector/PDMR Shareholding
11th Apr 20247:00 amRNSNotice of Analyst & Investor Meetings, FY Results
19th Mar 20243:29 pmRNSHoldings in Company
13th Mar 20248:30 amRNSDirector/PDMR Shareholding
1st Mar 20248:58 amRNSNotice of Results
14th Feb 20241:00 pmRNSDirector/PDMR Shareholding
13th Feb 20244:28 pmRNSDirector/PDMR Shareholding
1st Feb 20241:10 pmRNSHolding(s) in Company
29th Jan 20247:00 amRNSHolding(s) in Company
25th Jan 20247:00 amRNSTrading Update
19th Jan 20243:01 pmRNSHolding(s) in Company
12th Jan 20244:53 pmRNSHolding(s) in Company
12th Jan 20243:04 pmRNSHolding(s) in Company
11th Jan 20243:23 pmRNSDirector/PDMR Shareholding
14th Dec 20239:15 amRNSDirector/PDMR Shareholding
28th Nov 20237:00 amRNSDirector Dealings
27th Nov 20237:00 amRNSDirector Dealings
24th Nov 20237:00 amRNSTrading Update
15th Nov 20233:29 pmRNSHolding(s) in Company
13th Nov 20234:57 pmRNSDirector/PDMR Shareholding
30th Oct 20233:51 pmRNSHolding(s) in Company
18th Oct 202312:41 pmRNSHolding(s) in Company
11th Oct 20235:14 pmRNSDirector/PDMR Shareholding
21st Sep 20231:06 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.